Extensive preclinical data have demonstrated that leucovorin can modulate 5-fluorouracil (5-FU) cytotoxicity. Additionally, randomized clinical trials have shown that leucovorin increases the therapeutic index of 5-FU in patients with advanced colorectal cancer, setting a new therapeutic standard fo
Clinical experience with leucovorin and 5-fluorouracil
โ Scribed by Leslie R. Laufman; Wayne D. Brenckman Jr; Kathy A. Stydnicki; E. D. Morgan; Mary Collier; Victoria B. Knick; David S. Duch; Robert Mullin; Robert Ferone
- Publisher
- John Wiley and Sons
- Year
- 1989
- Tongue
- English
- Weight
- 493 KB
- Volume
- 63
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
## Background: Colorectal carcinoma is the third leading cause of cancer-related death. the primary treatment for patients with metastatic colorectal carcinoma is systemic chemotherapy with 5-fluorouracil (5-fu) and leucovorin (lv), a biomodulator of 5-fu that has been shown to enhance its activity
## BACKGROUND. The biochemical modulation of 5-fluorouracil (5-FU) by leucovorin (Lv) has demonstrated significantly increased response rates in comparison with the use of 5-FU alone in patients with advanced colorectal carcinoma. However, the higher response rate of LV/5-FU may occur at the expen